INTRODUCTIONAtopic dermatitis (AD) is a skin disorder characterized by chronic relapsing pruritic eczema resulting from altered skin barrier function and neuroimmune dysregulation.1 Moderate-to-severe AD can result in functional impairment, sleep…
Read More
INTRODUCTIONAtopic Dermatitis (AD) is a common, chronic, inflammatory dermatosis and skin disease that follows a relapsing pattern and requires a dynamic and stepwise approach to management.1,2 AD is often associated…
Read More
INTRODUCTIONCommon warts, also known as verruca vulgaris, are benign skin and mucosal growths caused by human papillomavirus (HPV) infection of keratinocytes.1 Common warts can occur at virtually any anatomic location,…
Read More
INTRODUCTIONAtopic dermatitis (AD) is a pruritic, inflammatory skin disease that affects approximately 5–30% of children and 2–10% of adults.1-3 The pathogenesis of AD involves a complex interplay of skin barrier…
Read More
In this supplement:Colloidal Oatmeal Part I: History, Basic Science, Mechanism of Action, and Clinical Efficacy in the Treatment of Atopic DermatitisColloidal oatmeal has a long-standing history in the treatment of…
Read More
INTRODUCTIONHistory of Oatmeal Oatmeal has a longstanding and rich history pertaining to its dermatologic use. The first documentation of oatmeal for skin health dates back as early as 2000 BC…
Read More
INTRODUCTIONAtopic Dermatitis in Skin of ColorIn Part I, we examined the ways in which colloidal oatmeal can be beneficial in the treatment of AD. Colloidal oatmeal has also been found…
Read More
INTRODUCTIONAtopic dermatitis (AD) is a chronic, inflammatory skin disease affecting 2%–7% of adults globally.1-3 While itch has been reported as the hallmark and most burdensome symptom of AD,4 other symptoms…
Read More
INTRODUCTIONHistory of Transient Acantholytic Dermatosis (Grover Disease) Transient acantholytic dermatosis, or Grover disease, is a rare acantholytic skin disorder that was first described by Dr. Ralph Weir Grover.1 Over the…
Read More
INTRODUCTIONIncobotulinumtoxinA (INCO; Xeomin®, Bocouture®; Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) is the only commercially available botulinum toxin A (BoNT/A) preparation free from complexing proteins.1 INCO is currently approved in…
Read More
To the Editor, We read, with interest, Maarouf et al’s study, Skin cancer epidemiology and sun protection behaviors among Native Americans (J Drugs Dermatol. 2019; 18(5):420- 423), which provided insight…
Read More
INTRODUCTIONSkin of color patients with psoriasis face unique challenges related to disease characteristics and treatment. Distribution and severity of psoriasis may be greater in patients with skin of color.1,2 Dyspigmentation—including…
Read More
